NMD4C Launches Clinical Summer School
We are excited to announce our inaugural Clinical Summer School, happening in Ottawa, Ontario on September 10–11, 2025.
The event will feature hands-on workshops designed to complement the NMD4C Royal College–accredited National Neuromuscular Lecture Series and foster engagement among fellows.
Supporting clinical trainees is a core priority for NMD4C. The Clinical Summer School will provide a unique environment for participants to refine diagnostic and analytical skills under the guidance of leading Canadian neuromuscular experts, while encouraging professional networking and mentorship. These fellows are also part of NMD4C’s 4th annual National Neuromuscular Lecture Series and represent the next generation of leaders in neuromuscular care.
To make it easier for trainees to attend, there will be no registration fees, with financial support available for both travel and accommodation.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.